Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome BioscienceTSE:4583 -1.43%38 Altman Z-Score is 6.31 as of Jul. 25, 2026, which is 51% below its 10-year median of 12.84. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 928 Biotechnology companies, Chiome Bioscience ranks better than 54.42% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.28 is strong.
Chiome Bioscience has a Altman Z-Score of 6.31, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Chiome Bioscience's Altman Z-Score or its related term are showing as below:
TSE:4583'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.85 Med: 12.84 Max: 29.93
Current: 3.28
During the past 13 years, Chiome Bioscience's highest Altman Z-Score was 29.93. The lowest was 1.85. And the median was 12.84.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Chiome Bioscience Altman Z-Score Related Terms
Chiome Bioscience Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Chiome Bioscience's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Chiome Bioscience's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7125
+
1.4
*
-1.3392
+
3.3
*
-0.4107
+
0.6
*
13.9895
+
1.0
*
0.2896
=
6.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Chiome Bioscience (TSE:4583) has a Altman Z-Score of 6.31 as of Jul. 25, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Chiome Bioscience and its competitors. This is 51% below median its historical median of 12.84. Over the past decade, Chiome Bioscience's Altman Z-Score has ranged from 1.85 to 29.93. According to the industry distribution chart, Chiome Bioscience ranks #423 out of 928 companies in the Biotechnology industry, placing it in the top 45.6%.
Is Chiome Bioscience's Altman Z-Score too high?
Chiome Bioscience's current Altman Z-Score of 6.31 is 51% below median its 10-year median of 12.84. Over the past 10 years, this metric has ranged from a low of 1.85 to a high of 29.93. The Biotechnology industry median Altman Z-Score is 2.55. Chiome Bioscience's value of 6.31 is 147.9% above this industry median. Based on the distribution chart, Chiome Bioscience ranks #423 out of 928 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #423 out of 928 companies for Altman Z-Score. This puts Chiome Bioscience in the upper half of its industry. The industry median Altman Z-Score is 2.55. Chiome Bioscience's value of 6.31 is 147.9% above this benchmark. Historically, Chiome Bioscience's own Altman Z-Score has ranged from 1.85 to 29.93 over the past decade. While the company's 10-year median is 12.84 vs. the industry median of 2.55, Chiome Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.55, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Altman Z-Score of 6.31 is 147.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Altman Z-Score is 6.31, which is 51% below median its own 10-year median of 12.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current Altman Z-Score is 6.31, which is 51% below median its 10-year median of 12.84 and 147.9% above the Biotechnology industry median of 2.55. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Altman Z-Score is 6.31 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02.
GuruFocus considers Chiome Bioscience to be Possible Value Trap.
Key valuation signals for TSE:4583:
Altman Z-Score: 6.31 (51% below median its 10-year median of 12.84)
GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
Industry Position: 147.9% above the Biotechnology median (#423 of 928)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score
Get the complete analysis for TSE:4583
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
